Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $12,128.88 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $12,128.88. Following the sale, the senior vice president now owns 130,621 shares in the company, valued at $5,444,283.28. The trade was a 0.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total value of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.

Twist Bioscience Stock Performance

TWST traded up $2.05 on Monday, hitting $44.94. The company’s stock had a trading volume of 724,963 shares, compared to its average volume of 924,609. The firm has a market cap of $2.68 billion, a P/E ratio of -13.30 and a beta of 2.15. The company’s 50 day simple moving average is $45.40 and its 200-day simple moving average is $45.27. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. Analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Trading of Twist Bioscience

Several institutional investors have recently bought and sold shares of TWST. First Light Asset Management LLC bought a new position in Twist Bioscience in the fourth quarter valued at about $56,984,000. Marshall Wace LLP lifted its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock worth $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after acquiring an additional 532,040 shares during the last quarter. State Street Corp boosted its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of several research reports. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. TD Cowen restated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.